HuGE Literature Finder
Records
1
-
5
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 9 26 (1): 18-24. Joshi Smita S, Catenacci Daniel V T, Karrison Theodore G, Peterson Jaclyn D, Zalupski Mark M, Sehdev Amikar, Wade James, Sadiq Ahad, Picozzi Vincent J, Amico Andrea, Marsh Robert, Kozloff Mark F, Polite Blase N, Kindler Hedy L, Sharma Manish |
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens. Oncology letters 2016 Nov 12 (5): 4231-4237. Cui Chengxu, Shu Chang, Cao Dandan, Yang Yi, Liu Junbao, Shi Shuping, Shao Zhujun, Wang Nan, Yang Ting, Liang Hao, Zou Shanshan, Hu Songni |
Gly71Arg UGT1A1 polymorphism is associated with breast cancer susceptibility in Han Chinese women. Genetics and molecular research : GMR 2016 15 (3): . Shi J, Li L H, Duan X Y, Liu Q, Sun L L, Tian Y |
UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anti-cancer agents in medicinal chemistry 2012 Aug . Zhou CF, Ma T, Su Y, Ye ZB, Ji J, Yu YY, Zhang J, Liu BY, Zhu ZG |
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer science 2011 Oct 102 (10): 1868-73. Satoh Taroh, Ura Takashi, Yamada Yasuhide, Yamazaki Kentaro, Tsujinaka Toshimasa, Munakata Masaki, Nishina Tomohiro, Okamura Shu, Esaki Taito, Sasaki Yasutsuna, Koizumi Wasaburo, Kakeji Yoshihiro, Ishizuka Naoki, Hyodo Ichinosuke, Sakata Y |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: